Reveglucosidase Alfa

Summary

Reveglucosidase Alfa (CHEMBL3707295) is a phase-3 clinical-stage enzyme; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707295
Name	Reveglucosidase Alfa
Type	Enzyme
Max phase	3

Also known as: BMN 701, BMN-701, Gilt-rhgaa, Reveglucosidasa alfa, Reveglucosidase alfa, ZC-701, REVEGLUCOSIDASE ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01924845	PHASE3	TERMINATED	BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)
NCT01230801	PHASE1/PHASE2	COMPLETED	Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
NCT01435772	PHASE2	TERMINATED	Extension Study for Patients Who Have Participated in a BMN 701 Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).